Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Acadia reports its financial results, material events, and governance changes as it develops and commercializes medicines for neurological and rare diseases.
Acadia’s current reports on Form 8‑K include items such as quarterly and year‑to‑date financial results and updates on board composition. For example, the company has filed 8‑Ks to furnish press releases announcing results for the three and nine months ended September 30, 2025, and for the three and six months ended June 30, 2025, under Item 2.02 (Results of Operations and Financial Condition. Another 8‑K discloses the resignation of a member of the Board of Directors under Item 5.02, noting that the resignation was not due to any dispute or disagreement with the company or the Board.
In addition to 8‑Ks, Acadia files annual and quarterly reports that typically contain detailed discussions of its commercial portfolio, including NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as information on its pipeline programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, essential tremor, and other neuroscience and neuro‑rare indications. These filings generally address revenue composition, research and development spending, risk factors, and other information relevant to ACAD shareholders.
On Stock Titan, Acadia’s SEC filings are supplemented with AI-powered summaries that explain the key points of lengthy documents such as 10‑K annual reports, 10‑Q quarterly reports, and 8‑K current reports in plain language. Real-time updates from the SEC’s EDGAR system help users see new filings as they appear, while AI analysis highlights important changes in financial metrics, business priorities, and risk disclosures. Investors can also review insider-related filings such as Form 4 to monitor transactions by directors and officers in ACAD stock.
By combining original SEC documents with automated explanations, this filings page helps users quickly identify what Acadia is reporting about its financial condition, commercial performance, and development programs in neurological and rare diseases.
ACADIA PHARMACEUTICALS INC reported equity awards to its Principal Accounting Officer, James Kihara. He received a stock option for 21,766 shares of common stock at an exercise price of $22.16 per share and 6,332 restricted stock units, both as compensation-related grants.
According to the terms, 25% of the option vests and becomes exercisable on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments after that date. The restricted stock units vest in four equal annual installments beginning March 6, 2027, each unit representing the right to receive one share of common stock. These are routine compensation awards, not open‑market purchases or sales.
ACADIA PHARMACEUTICALS INC executive Jennifer J. Rhodes, EVP and Chief Legal Officer, received new equity compensation awards. She was granted a stock option for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty‑five percent of this option vests on March 6, 2027, with the remainder vesting in 36 equal monthly installments thereafter. She also received 26,382 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are compensation grants and do not reflect any open‑market buying or selling.
ACADIA PHARMACEUTICALS INC reported that EVP and Chief Financial Officer Mark C. Schneyer received new equity awards. He was granted stock options for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. According to the terms, 25% of these options vest and become exercisable on March 6, 2027, with the remaining options vesting in 36 equal monthly installments thereafter.
Schneyer was also granted 26,382 restricted stock units, each representing a contingent right to receive one share of common stock. These restricted stock units vest in four equal annual installments beginning on March 6, 2027. All transactions are classified as awards or grants rather than open-market purchases or sales.
ACADIA PHARMACEUTICALS EVP and Chief Commercial Officer Thomas Garner reported compensation-related equity awards. He received stock options for 97,947 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty-five percent of these options vest on March 6, 2027, with the rest vesting in 36 equal monthly installments. He was also granted 28,493 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are awards from the company, not open-market purchases or sales.
ACADIA PHARMACEUTICALS INC executive Elizabeth H.Z. Thompson, EVP and Head of Research & Development, received new equity awards. She was granted a stock option for 101,574 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036.
According to the vesting terms, 25% of this option will vest and become exercisable on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. She also received 29,548 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning March 6, 2027.
ACADIA PHARMACEUTICALS INC reported that Chief Executive Officer Owen Adams Catherine received new equity awards. She was granted stock options for 263,005 shares of common stock at an exercise price of 22.1600, vesting 25% on March 6, 2027, with the remainder vesting in 36 equal monthly installments and expiring on March 5, 2036. She also received 76,509 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These awards are compensation grants and do not involve any open-market purchases or sales.
Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole to its board of directors and Audit Committee, effective March 3, 2026, to fill a vacancy as a Class II director with a term running through the 2027 annual meeting.
Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $50,000 for board service and $12,500 for Audit Committee service, both prorated. He received an initial equity grant valued at $200,000, split equally between stock options and restricted stock units, vesting annually over three years, plus a prorated annual equity grant of $95,300 vesting over approximately one year. Beginning with the 2026 annual meeting, he will be eligible for annual equity grants with a target value of $400,000, also split between options and RSUs.
Baker Bros. Advisors and affiliated entities filed Amendment No. 17 to their Schedule 13D on ACADIA Pharmaceuticals Inc., reporting beneficial ownership of up to 43,294,373 shares of common stock, representing 25.4% of the company based on 170,494,613 shares outstanding as of February 18, 2026.
The amendment details board-related stock options, restricted stock units and common shares received by Julian C. Baker and Dr. Stephen R. Biggar, which are subject to the funds’ pecuniary interest, as well as prefunded warrants constrained by a 19.99% beneficial ownership cap. It also discloses a new registration rights agreement granting the Baker funds shelf resale registration and limited underwritten offering and block trade rights for their ACADIA securities.
Acadia Pharmaceuticals is a biopharmaceutical company focused on neurological and rare diseases, built around two commercial drugs: NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome. Net product sales from these medicines reached $1,071.5 million in 2025, up from $957.8 million in 2024, reflecting strong franchise growth.
The company is investing heavily in its pipeline, led by remlifanserin, now in Phase 2 trials for Alzheimer’s disease psychosis and Lewy Body Dementia psychosis, and ACP-211 in a Phase 2 study for major depressive disorder. It plans a Phase 2 trial of ACP-711 in essential tremor in late 2026 and a Phase 1 study of ACP-271 for tardive dyskinesia and Huntington’s disease in early 2026. ACP-101 for Prader‑Willi syndrome was discontinued after a Phase 3 failure.
Acadia is expanding DAYBUE globally, with approvals in Canada and Israel and an EU marketing application that recently received a negative trend vote, for which it intends to seek re‑examination. As of June 30, 2025, non‑affiliate market value was about $2.3 billion, and 170,494,613 shares were outstanding as of February 18, 2026.
Acadia Pharmaceuticals reported strong fourth-quarter and full-year 2025 results, with GAAP total revenues of $284 million for the quarter and $1.07 billion for the year, up 9% and 12% year over year.
Non-GAAP adjusted total revenues reached $298 million in the quarter and $1.08 billion for 2025, reflecting faster growth of 16% and 14%. NUPLAZID generated GAAP net sales of $174 million in Q4 and $680 million for the year, while DAYBUE delivered $110 million in Q4 and $391 million for 2025, both growing double digits.
Net income jumped to $274 million in Q4 and $391 million for 2025, helped by a non‑cash income tax benefit of $250 million. Cash, cash equivalents, and investment securities rose to $820 million. For 2026, Acadia guides total revenues of $1.22–$1.28 billion, with continued sales growth expected from NUPLAZID and DAYBUE.